Jefferies sees limited Generali upside after strong earnings-driven rally

Jefferies downgraded Generali to hold from buy, setting a €38 target price that is 12% below its €43.07 close after the insurer's shares gained 123% since January 2024. While the broker raised 2026 EPS estimates 7% to €3.30 and forecasts 2027 EPS up 5%, it believes much of the strategic improvement is now priced in following valuation expansion to more than 12x forward earnings. Jefferies cited deteriorating retail non-life pricing, less favorable weather conditions, life-policy lapse risk and competitive new-business margins as constraints on further estimate upgrades.

Analysis

Generali’s risk/reward has shifted from an operational-improvement story to a capital-return and execution-duration story: at the current valuation, even modest disappointment in retail P&C pricing, German life margins, or lapse experience can drive multiple compression before it materially affects reported earnings. The key asymmetry is that underwriting normalization hits both earnings quality and the market’s willingness to capitalize those earnings at a premium, making downside potentially larger than the next incremental EPS upgrade. The November results and Investor Day are the relevant 1-3 month catalysts, but management’s buyback framework—not another small earnings beat—will determine whether the premium can persist.

AXA offers the cleaner relative-value expression. It trades at a meaningful valuation discount despite a less demanding capital-return hurdle, while Generali requires sustained favorable combined-ratio performance and recurring buybacks to defend its premium. A deterioration in European motor/property pricing would pressure both names, but Generali has more multiple downside; conversely, a credible step-up in recurring capital returns could quickly invalidate the short leg. Over 6-18 months, European insurers remain structurally supported by capital generation, but competitive life pricing and catastrophe volatility argue against paying peak multiples for the most re-rated name.

The contrarian risk is that consensus may be too focused on underwriting deceleration and underweight the value of a durable buyback commitment. If the Investor Day formalizes materially higher recurring repurchases without impairing solvency, the market can bridge a period of softer organic earnings and re-rate the stock toward the bull-case valuation. This is therefore a relative-value setup rather than a high-conviction outright short ahead of capital-allocation catalysts.

Key Decisions for Investors

• Initiate a 3-6 month pair: long AXA (CS.PA) / short Generali (G.MI), beta- and euro-neutral. Target 10-15% relative outperformance as valuation dispersion normalizes; stop out if Generali announces a recurring buyback program materially above the currently embedded baseline or if the spread widens another 8%.
• Do not add to Generali outright ahead of the November results. Reassess only if management demonstrates stable lapse trends, non-life loss performance consistent with a low-90s combined ratio, and capital returns sufficient to support the current premium; absent all three, treat rallies as short-entry opportunities.
• For existing Generali longs, reduce exposure into the Investor Day or hedge with 3-6 month downside puts if liquid pricing is available. The event risk is asymmetric because incremental earnings upgrades appear largely capitalized, while weaker pricing commentary can trigger both 2027 EPS cuts and P/E de-rating.
• Monitor Allianz (ALV.DE) as a sector read-through rather than a primary trade. Broad European insurance multiple compression following weaker commercial/retail pricing would favor a modest short in ALV only if its valuation premium remains intact; otherwise AXA is the preferred long exposure.